Community
Lipedema research moves. The Elora newsletter moves with it, and translates it into language you can actually use.
Community
Lipedema research moves. The Elora newsletter moves with it, and translates it into language you can actually use.
The Elora newsletter is a monthly plain-language digest of what is happening in Lipedema research and practice. It covers new and updated studies, practical management notes, community updates, and policy news. It contains no advertising and no sponsored content.
Lipedema research has been quiet for most of the eighty-plus years since Allen and Hines first described the condition at the Mayo Clinic in 1940. That is changing. In the last few years, peer-reviewed studies have examined Lipedema tissue at a molecular level, tracked outcomes across management approaches, documented the psychological burden of the condition, and debated what clinical guidelines should say. It is genuinely a good time to be paying attention, if you have the tools to do so.
The Elora newsletter is built for people who want to stay informed but who do not have the time, the access, or the appetite to comb through journal databases every month. Each issue takes one significant piece of new or updated research and explains what it found, what its limitations are, and what it might mean for someone managing Lipedema. We are clear about the difference between strong, replicated evidence and findings that are preliminary or contested. We do not round up to optimism when the data is more complicated than that.
The newsletter goes out monthly, with occasional additional issues when something particularly significant is published or announced. We also cover advocacy and policy developments, because how Lipedema is recognised and funded by health systems has direct consequences for access to diagnosis and care. If there is movement on that front, readers should know about it. A full archive of past issues is in development and will be available on this page.
Who writes it: the newsletter is produced by the Elora team. It is not written by or for pharmaceutical companies, medical device manufacturers, or anyone else with a financial interest in Lipedema treatment. There is no sponsored content, no advertising, and no affiliate arrangements. The editorial position is simple: cover the science honestly, say what is known and what is not, and trust readers to make their own decisions from there.
Evidence rating: Strong for the research covered in the newsletter. Lipedema science has accelerated considerably in recent years. Studies on disease mechanisms, management strategies, and quality of life are now being published with real regularity, including a 2025 progress review in PMC, a Nature article on emerging discoveries, and ongoing clinical guidance from NIH-affiliated sources. The newsletter draws on this body of work directly.
The Elora editorial approach is to describe what studies found, note where evidence is strong and where it is still emerging, and be honest about what is not yet known. We do not promote treatments. We do not accept money from companies with a commercial interest in what we cover.
Most Lipedema research is published in journals written for clinicians and researchers. Getting through the language alone takes effort, and knowing which papers are worth your attention takes more. The newsletter does that work so you do not have to. You get the findings, the caveats, and a clear note on what any of it might mean in practice, in language that does not require a medical degree to follow.